This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AMU865. CME credit will be available until April 2, 2025.

Navigating Advances in Alzheimer’s Disease: An Expert Consult on Integrating the New Diagnostic Tools and Disease-Modifying Therapies Into Your Clinical Practice

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Eisai Inc.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MCV865. CME/AAPA credit will be available until March 14, 2025.

Improving the Recognition and Management of Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer’s Disease Treatment: Practical Tools & Strategies for Radiology & Neuroradiology Specialists

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Jerome A. Barakos, MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
Tammie L.S. Benzinger, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Avid Radiopharmaceuticals/Lilly; Biogen; and Eisai Co., Ltd.
Grant/Research Support from Hyperfine, Inc. and Siemens.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.

Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Manmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.

FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from argenx US, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
James F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.
Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.


Faculty/Planner
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.


Faculty/Planner
Claire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CRG865. CME/AAPA credit will be available until November 5, 2024.

Building a Better Bridge: Providing Continuous SMA Care From Adolescence Through Adulthood

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Claudia A. Chiriboga, MD, MPH, FAAN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Novartis Pharmaceuticals Corporation/AveXis.
Grant/Research Support from Biogen; Biohaven, Ltd.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Novartis Pharmaceuticals Corporation/AveXis.


Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NQQ865. CME credit will be available until November 9, 2024.

From Early Recognition to Age- and Stage-Appropriate Care: Navigating a New Era in Rett Syndrome Management

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from ACADIA Pharmaceuticals Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Alan K. Percy, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acadia Pharmaceuticals Inc.; Neurogene Inc.; and Taysha Gene Therapies, Inc.
Grant/Research Support from Acadia Pharmaceuticals Inc.


Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UDJ865. CME credit will be available until November 20, 2024.

Honing Diagnostic and Management Skills: The Role of the Pediatrician in the New Era of Rett Syndrome Management

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from ACADIA Pharmaceuticals Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Eric Marsh, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acadia Pharmaceuticals Inc. and Stoke Therapeutics.
Grant/Research Support from Acadia Pharmaceuticals Inc.; Curaleaf, Inc.; Epygenix Therapeutics, Inc.; Marinus Pharmaceuticals, Inc.; Stoke Therapeutics; and Takeda Pharmaceutical Company Limited.


Faculty/Planner
David N. Lieberman, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acadia Pharmaceuticals Inc.; Anavex Life Sciences Corp.; Neurogene Inc.; and Taysha Gene Therapies, Inc.
Grant/Research Support from Acadia Pharmaceuticals Inc.; Anavex Life Sciences Corp.; and Jazz Pharmaceuticals, Inc.


Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.

Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
James D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.
Data Safety Monitoring Board for Sanofi.


Co-Chair/Planner
Sabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.
Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.


Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete NCPD/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/EUC865. NCPD/CE/AAPA credit will be available until November 11, 2024.

Realizing the Potential of Rapid-Acting Treatments for Depression: Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care

Optimal management of depression begins with adequate screening and early introduction of appropriate therapy. However, monoaminergic antidepressant therapies, which are currently considered the standard of care, have several limitations, such as slow therapeutic response times, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence.

Recent research has focused on novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. For example, neuroactive steroids such as zuranolone act as positive allosteric modulators of the GABA-A receptor. In 2023, zuranolone became the first and only oral therapy to be approved for the treatment of postpartum depression. There have also been advances in glutamatergic antidepressants, with the approval of esketamine nasal spray for treatment-resistant depression in 2019 and for depression with acute suicidal ideation or behavior in 2020, as well as the approval of dextromethorphan-bupropion for the treatment of major depressive disorder in 2022.

In order to help clinicians remain abreast of the latest treatment options for depression, PeerView recently held a Candid Conversations & Clinical Consults educational symposium, featuring a panel of psychiatric–mental health nursing faculty. These depression experts paired compelling, real-world case scenarios with practice-changing evidence to illustrate how to integrate novel and emerging treatments for depression into clinical practice, including strategies to identify patients who may benefit from these treatments, and how to use shared decision-making to craft individualized treatment plans. If you couldn’t watch the live event, this on-demand version is available now!

Co-Chair & Moderator
Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP
The Hamilton Group Behavioral Health LLC
Las Vegas, Nevada

Co-Chair & Presenter
Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE
Rasmussen University
Bloomington, Minnesota

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sage Therapeutics and Biogen.

Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Josh Hamilton, DNP, RN/PMH-BC, FNP-C, PMHNP-BC, CTMH, CNE, CLNC, FAANP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alkermes and Point of Care Network, LLC (POCN).
Speaker for Myriad Neuroscience and Point of Care Network, LLC (POCN).


Co-Chair/Planner
Rhone D'Errico, DNP, MBA, APRN, FNP-BC, PMHNP-BC, ENP-C, CNE, ACUE, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Point of Care Network (POCN).
Speaker for Lippincott Clinical Pulse and Practical Updates in Primary Care.


Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Go online to PeerView.com/VWR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Due to the rarity of Rett syndrome and overlapping symptoms with other, more common neurodevelopmental disorders, diagnosis is challenging and often missed or delayed. With one Rett-targeted therapy recently approved and others in development, clinicians now have the opportunity to offer not merely symptom management but potential clinical improvement. This PeerView case-based activity is designed to improve your ability to recognize, diagnose, and treat patients with Rett syndrome. Each session features a realistic case discussion with expert faculty panelists sharing the evidence that supports clinical decisions for timely diagnosis and early initiation of multidisciplinary management and targeted therapy as appropriate. Upon completion of this activity, participants should be better able to: Apply diagnostic criteria to provide a timely diagnosis of Rett syndrome in patients demonstrating subtle signs and symptoms; Employ evidence-based, age-appropriate care for patients with Rett syndrome in alignment with consensus management guidelines; and Evaluate the evidence surrounding the safety, efficacy, and tolerability of new and emerging therapies for the treatment of Rett syndrome.

Go online to PeerView.com/CTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) was identified as a distinct demyelinating disease entity only recently. Prior to this characterization of MOGAD, many patients were considered to have a variant of MS, NMOSD, or other neurologic condition. Now an international panel of experts has proposed diagnostic criteria that, when validated, promise to improve MOGAD diagnostic accuracy and confidence. This is particularly important, given that several clinical trials are investigating potential treatments for MOGAD. This unique PeerView activity will use problem-based educational interventions to expose learners to the science and clinical experience behind accurate diagnosis and best practices in management of MOGAD. You will be able to employ optimal clinical decision-making for your patients with MOGAD that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Explain the diagnostic criteria for MOGAD as proposed by the International MOGAD Panel; Employ recommended diagnostic tools (eg, the MOG antibody test, relevant MRI findings) to identify MOGAD and distinguish it from other demyelinating diseases; and Implement therapeutic strategies to provide acute treatment and relapse prevention in patients with MOGAD.